Hogan Lovells represents Gilead Sciences and Kite Pharma in collaboration and license agreement with oNKo-innate Pty. Ltd.

Northern Virginia, 24 April, 2020 – Hogan Lovells represented biopharmaceutical companies Gilead Sciences and Kite Pharma in their cancer immunotherapy research collaboration with oNKo-innate Pty. Ltd. to support discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells.

Under the collaboration, oNKo-innate will execute screens to identify and validate targets to seed internal Gilead immuno-oncology discovery programs, and will create and evaluate NK constructs for Kite’s development of next-generation cell therapies.

The Hogan Lovells team advising Gilead and Kite included Northern Virginia partner Cullen Taylor, Washington, DC partner Adam Bellack, and Northern Virginia associate Rachel Eisen.


Back To Listing

Loading data